Results 211 to 220 of about 1,934,057 (295)
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu+11 more
wiley +1 more source
Decomposed Gaussian Processes for Efficient Regression Models with Low Complexity. [PDF]
Fradi A, Tran TT, Samir C.
europepmc +1 more source
B‐cell chronic lymphocytic leukemia (B‐CLL) and monoclonal B‐cell lymphocytosis (MBL) show altered proteomes and phosphoproteomes, analyzed using mass spectrometry, protein microarrays, and western blotting. Identifying 2970 proteins and 316 phosphoproteins, including 55 novel phosphopeptides, we reveal BCR and NF‐kβ/STAT3 signaling in disease ...
Paula Díez+17 more
wiley +1 more source
Using the Genetic Algorithm to Maximize the Likelihood Function of Normal Distribution
openalex +1 more source
Joint likelihood function of cluster counts and
Emmanuel Schaan+2 more
openalex +1 more source
Variable Selection for Progressive Multistate Processes Under Intermittent Observation. [PDF]
Li X, Cook RJ, Diao L.
europepmc +1 more source
Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley +1 more source
ProtNote: a multimodal method for protein-function annotation. [PDF]
Char S+4 more
europepmc +1 more source
Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen+12 more
wiley +1 more source
Loss formulations for assumption-free neural inference of SDE coefficient functions. [PDF]
Vaisband M+4 more
europepmc +1 more source